Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.

CNS Oncol · 2018 · PMC6200060 · PMID 30124334

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This estimated increase in mean lifetime survival of 1.8 years is highly significant for a disease with an historical median survival of just over a year.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.